The only curative treatment for proximal bile duct cancer with involvement of both main hepatic ducts is liver transplantation. Most patients do not fulfill the requirements for liver transplantation. Our treatment strategy in appropriate cases is palliative tumor resection and reconstruction of the biliary passage by sutureless bilioenteric anastomosis. We have treated 12 patients, 5 in combination with intraluminal and percutaneous radiotherapy. Our results indicate that this strategy leads to effective palliation in some cases provided that only microscopic residual tumor is left in-situ. Our survival times compare favourably with survival after liver transplantation.
INTRODUCTION
Bile duct cancer is a rare tumor accounting for 7% of all gastrointestinal malignancies1. According to its location it can be subdivided into distal, intermediate and proximal tumors2. This classification is essential as treatment policy depends on tumor location.
In the past proximal bile duct tumors were classified into three types, according to their extension in relation to the hepatic confluence3 considerations it is deemed useful to add a fourth type of proximal bile duct tumor which is characterized by invasion of both main hepatic ducts 4 ( Figure 1 ).
A prerequsite for potentially curative resection of proximal bile duct cancer is that major structures of the porta hepatis like the portal vein and the hepatic artery are, either, not invaded by the tumor or that their continuity can be reconstructed after partial resection5 '6 (Figure 4 ). The radiation, calculated at 0.5 cm from the wire, was then Following discharge a continuous decline of serum bilirubin to normal levels was observed in 7 patients. In two patients with gross residual tumor a postoperative increase of serum bilirubin was observed. Both patients died of disease 2 and 3 months later, respectively. Two patients with gross residual tumor exhibited a delayed decrease in serum bilirubin, they survived 5 and 7 months, respectively ( Figure 5 ). Ten patients died of disease in the observation period ( Table 1) . The mean survival time at this writing is 11.5 months, the median survival time is 10 months. In the one surviving patient serum bilirubin is still in normal range. Five 4 . have no severe concommitant disease should be selected for this procedure6.
These selection criteria almost always lead to exclusion of patients with bile duct cancer, since the vast majority of patients presenting with this disease are over 60 years of age22. Therefore the appropriate surgical management of advanced proximal bile duct tumors is still not firmly established. None of our patients would have been a candidate for liver transplantation.
Our therapeutic concept of palliative tumor resection and additive combined radiotherapy is based on the idea that a radical resection of tumors which involve both main hepatic ducts is not possible for anatomical reasons. Residual disease is 10 16 23 treated by radiotherapy This concept has been already described by Langer et al. and Cameron et al. ', but mostly for tumors which involve the hepatic confluence and do not invade the level of the second order bile ducts. In Cameron's series a mean survival time of 18 months was reported which seems to be more favorable than our experience with a mean survival time of 11.5 months. This difference could be explained by the fact, that 37% of patients in Cameron's series were resected with a curative intent, whereas in our series the localisation of the tumor was so unfavorable that only a palliative tumor resection could be carried out. Involvement of the resection margins by bile duct cancer is supposed to have a negative effect on survival, but this issue has been questioned in a recent study6.
In our experience, the palliation is especially favourable in patients where no gross residual disease is evident (R-l-resection (Figure 3 ). In the case of a sutured anastomosis, most often several thin biliary stents are introduced, which do not provide a lumen wide enough for introduction of the iridium wire.
Bile duct cancer can be considered as a radiosensitive tumor16'18'19'23. In patients, treated by palliative drainage procedures with the tumors left in place, radiation therapy was able to induce prolongation of the average survival time16. In addition, regressive changes have been observed in irridiated tumors25. Intraluminal radiotherapy with 192-Iridium led to prolongation of survival as well; nearly 50% of patients survived for more than 12 months19'24. This figure is surprisingly high in view of our results, but the fact has to be considered that in these series bile duct tumors of all locations were included, whereas our series was comprised of patients with a particularly dismal prognosis due to advanced tumors involving both lobes of the liver. So far, the question whether palliative resection of the tumor or radiotherapy alone will lead to better palliation, cannot be answered. A prospective controlled clinical randomized trial is necessary for further evaluation.
A major set back to palliative biliary decompression combined with internal radiation therapy is the substantial mortality and morbidity, especially the high incidence of cholangitis, reaching a rate of up to 40% 19. However, in a recent study, a mortality of zero and an incidence of cholangitis of 14% were described, with a median survival of 10.5 monthsTM.
Our approach to treatment of proximal bile duct cancer combines the advantages of intraluminal and percutaneous radiation therapy with improvement of quality of life, which results from palliative tumor resection. Due to our limited number of patients so far we cannot prove that additive radiotherapy indeed leads to prolongation of survival. The comparison of our approach to liver transplantation shows that our patients presented with a more unfavorable prognosis due to advanced age and concommitant risk factors. Nonetheless, the average survival time of our series was 11.5 months (median 10 months) as compared to a recent 
